Tevogen Bio Receives Nasdaq Non-Compliance Notice Over Market Value
Summary
Tevogen Bio Holdings Inc. has disclosed receiving notices from Nasdaq on April 16 and 17, 2026, indicating non-compliance with continued listing rules. The company failed to meet the $50 million market value of listed securities and $15 million market value of publicly held shares requirements for the Nasdaq Global Market. This development is particularly concerning given the company's recent 10-K filing (March 31, 2026), which reported a significantly increased net loss and a precarious cash position of only $0.6 million, alongside a default on notes payable. While Tevogen Bio has 180 days to regain compliance, this notice significantly elevates the risk of delisting and further complicates its ability to secure financing, impacting investor sentiment. Traders will closely monitor the company's strategy to address these critical financial and compliance issues.
At the time of this announcement, TVGN was trading at $8.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $33.9M. The 52-week trading range was $4.14 to $75.50. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.